Related Experiment Video
Updated: Apr 26, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?
1Department of Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH, UK. darren.hargrave@nhs.net.
Abstract:
Pediatric diffuse intrinsic pontine glioma (DIPG) has a dismal prognosis that has not seen a change in outcome despite multiple clinical trials. Possible reasons for failure to make progress in this aggressive childhood brain tumor include: poor understanding of the underlying molecular biology due to lack of access to tumor material; absence of accurate and relevant DIPG preclinical models for drug development; ill-defined therapeutic targets for novel agents; and inadequate drug delivery to the brainstem. This review will demonstrate that systematic studies to identify solutions for each of these barriers is starting to deliver progress that can turn pessimism to optimism in DIPG.
Insights
Pediatric diffuse intrinsic pontine glioma (DIPG) remains a challenging childhood brain tumor with poor outcomes. However, addressing key research barriers is now paving the way for improved therapeutic strategies and optimism.
Area of Science:
- Pediatric neuro-oncology
- Cancer biology
- Translational research
Background:
- Pediatric diffuse intrinsic pontine glioma (DIPG) has a dismal prognosis with no significant improvement in patient outcomes despite numerous clinical trials.
- Aggressive childhood brain tumor characterized by limited understanding of molecular drivers, lack of suitable preclinical models, undefined therapeutic targets, and poor drug delivery to the brainstem.
Purpose of the Study:
- To review the challenges hindering progress in DIPG treatment.
- To highlight systematic research efforts addressing these barriers.
- To present a more optimistic outlook for DIPG therapeutic development.
Main Methods:
- Literature review of studies addressing DIPG research barriers.
- Analysis of progress in understanding DIPG molecular biology.
- Evaluation of advancements in DIPG preclinical models and drug development.
Main Results:
- Lack of tumor material hinders molecular understanding.
- Absence of accurate preclinical models impedes drug development.
- Therapeutic targets remain ill-defined, and drug delivery to the brainstem is inadequate.
Conclusions:
- Systematic studies are beginning to overcome DIPG research barriers.
- Progress in understanding biology, models, and targets offers new hope.
- These advancements may lead to improved outcomes for children with DIPG.
